RUBY — Rubius Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Rubius Therapeutics Appoints Dannielle Appelhans As Chief Operating Officer
Brief: Rubius Therapeutics Announces First Patient Dosed With Rtx-240 In Combination With Keytruda For The Treatment Of Advanced Solid Tumors
Brief: Rubius Therapeutics Announces Publication Of Rtx-321 Preclinical Data In Nature Communications
Rubius Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Rubius Therapeutics Posts Qtrly Loss Per Share $0.51
Brief: Rubius Therapeutics Announces First Patient Dosed In Phase 1 Clinical Trial Of RTX-321
Brief: Rubius Therapeutics Presents Initial Clinical Results From The Ongoing Phase 1/2 Clinical Trial Of RTX-240
U.S. RESEARCH ROUNDUP- Adobe, Intel, Wingstop
Rubius Therapeutics: Down on discounted stock pricing
U.S. RESEARCH ROUNDUP- East West Bancorp, Genmark Diagnostics, iHeartMedia
Brief: Rubius Therapeutics Commences Underwritten Public Offering Of $150 Million Of Shares Of Its Common Stock
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:07 AM
Brief: Rubius Therapeutics Reports Fourth Quarter And Full Year 2020 Financial Results
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:07 AM
Brief: Rubius Therapeutics Reports Q3 Loss Per Share Of $0.51
Brief: Rubius Therapeutics Announces Dosing Of First Patient In Acute Myeloid Leukemia Trial
Brief: Rubius Therapeutics To Present At Society For Immunotherapy Of Cancer's Annual Meeting Preclinical Data From Oncology Program
Brief: Rubius Therapeutics Appoints Jose Carmona As Chief Financial Officer
Brief: Rubius Therapeutics Reports Q2 Loss Per Share $0.47